Off-the-Shelf Realities – Where Are We Now? Featuring OmnImmune® and the Evolving Landscape of Allogeneic Cell Therapy
18 Sep 2025
Allogeneic Access: Engineering the Future of Cell Therapy
- Exploring lessons from OmnImmune®’s transition from fresh to cryopreserved gamma-delta T cells in relapsed/refractory AML.
- Addressing key hurdles in life-saving material (LSM) release strategies, maintaining potency across freeze-thaw cycles, and consistency in donor-derived products.
- Open discussion on managing donor variability, release assays, and potency programs in the push toward scalable off-the-shelf solutions.
Industry Expert
